Journal of Clinical Microbiology · 2005 · 141 citations · 9 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMedical MicrobiologyMycologyAntibiotic ResistanceAntifungal ResistanceAntifungal TherapyAntimicrobial Susceptibility TestingFungal DiagnosticsFungal InfectionsAntibiotic Susceptibility Data AnalysisAntibiotic Susceptibility TestingAntifungal Susceptibility TestingBroth MicrodilutionFluconazole TherapyFungal Drug ResistanceNon-albicans Candida SpeciesResistance In Clinical Isolates
The aim of this study was to compare MICs of fluconazole, itraconazole, posaconazole, and voriconazole obtained by the European Committee on Antibiotic Susceptibility Testing (EUCAST) and CLSI (formerly NCCLS) methods in each of six centers for 15 Candida albicans (5 fluconazole-resistant and 4 susceptible-dose-dependent [S-DD] isolates), 10 C. dubliniensis, 7 C. glabrata (2 fluconazole-resistant isolates), 5 C. guilliermondii (2 fluconazole-resistant isolates), 10 C. krusei, 9 C. lusitaniae, 10 C. parapsilosis, and 5 C. tropicalis (1 fluconazole-resistant isolate) isolates. CLSI MICs were obtained visually at 24 and 48 h and spectrophotometric EUCAST MICs at 24 h. The agreement (within a 3-dilution range) between the methods was species, drug, and incubation time dependent and due to lower EUCAST than CLSI MICs: overall, 94 to 95% with fluconazole and voriconazole and 90 to 91% with posaconazole and itraconazole when EUCAST MICs were compared against 24-h CLSI results. The agreement was lower (85 to 94%) against 48-h CLSI endpoints. The overall interlaboratory reproducibility by each method was > or =92%. When the comparison was based on CLSI breakpoint categorization, the agreement was 68 to 76% for three of the four species that included fluconazole-resistant and S-DD isolates; 9% very major discrepancies (< or =8 microg/ml versus > or =64 microg/ml) were observed among fluconazole-resistant isolates and 50% with voriconazole (< or =1 microg/ml versus > or =4 microg/ml). Similar results were observed with itraconazole for seven of the eight species evaluated (28 to 77% categorical agreement). Posaconazole EUCAST MICs were also substantially lower than CLSI MIC modes (0.008 to 1 microg/ml versus 1 to > or =8 microg/ml) for some of these isolates. Therefore, the CLSI breakpoints should not be used to interpret EUCAST MIC data.
9
Manuel Cuenca‐Estrella, Caroline B. Moore, Francesco Barchiesi et al. · Clinical Microbiology and Infection · 2003 · 159 citations · Full text
Manuel Cuenca‐Estrella, Wendy Lee‐Yang, Meral A. Cıblak et al. · Antimicrobial Agents and Chemotherapy · 2002 · 131 citations · Full text
Erja Chryssanthou, Manuel Cuenca‐Estrella · Journal of Clinical Microbiology · 2002 · 113 citations
Ana Espinel-Ingroff, J. L. Rodriguez-Tudela, Joaquı́n V. Martı́nez-Suárez · Journal of Clinical Microbiology · 1995 · 81 citations · Full text
Juan L. Rodrı́guez-Tudela, JoaquinV. MartinezSuárez, Fernando Dronda et al. · Journal of Antimicrobial Chemotherapy · 1995 · 75 citations